Open AccessImpact of second look laparotomy and secondary cytoreductive surgery at second‐look laparotomy in ovarian cancer patients
Author(s) -
Obermair Andreas,
Sevelda Paul
Publication year - 2001
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1034/j.1600-0412.2001.d01-10.x
Subject(s) - medicine , laparotomy , cytoreductive surgery , ovarian cancer , chemotherapy , clinical endpoint , surgery , stage (stratigraphy) , cancer , randomized controlled trial , paleontology , biology
Objective. Currently, no prospective study supports or refutes the value of secondary cytoreductive surgery in patients with ovarian cancer. We therefore reviewed the surgical data of patients who underwent second‐look laparotomy (SLL) with or without secondary cytoreductive surgery at our department. Methods. Analysis is based on the data of 179 patients who had FIGO stage II (suboptimally staged), stage III or IV ovarian cancer, who received a platinum‐based first‐line chemotherapy, who were clinically considered to be tumor‐free or had at least a clinically partial response to first‐line chemotherapy, and who underwent SLL. In patients with macroscopic tumor the diagnostic SLL was followed by a secondary cytoreductive surgery in order to remove as much tumor as possible. Patients with a positive SLL were given second‐line chemotherapy. Survival from SLL until death was considered the primary statistical endpoint. Results. In 78 out of 179 (43.5%) a negative SLL could be confirmed pathologically. Patients with negative findings, with microscopic, and macroscopic disease at SLL had a median survival of 66.6, 57.2, and 19.0 months, respectively ( p =0.0001). In patients who underwent a secondary cytoreductive operation and in whom residual tumor was none, less than 2 cm, or more than 2 cm, the median survival was 22.9, 17.8, and 15.5 months, respectively ( p =0.325). Conclusions. The presence of macroscopic tumor at SLL is an adverse prognostic factor whereas the role of secondary cytoreductive surgery at SLL appears to be limited in the routine management of ovarian cancer patients.